cfz533
mAbexperimental
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
12
Phase 3
0
Phase 4
0
Earliest trial started Jan 7, 2013 (NCT02089087)
Timeline
Indications
Studied for
- Arthritis, Rheumatoid · Phase 1
- Diabetes Mellitus, Type 1 · Phase 2
- Graves Disease · Phase 2
- Hidradenitis Suppurativa · Phase 2
- Kidney Transplantation · Phase 2
- Liver Transplantation · Phase 2
- Lupus Erythematosus, Systemic · Phase 2
- Lupus Nephritis · Phase 2
- Myasthenia Gravis · Phase 2
- Sjogren's Syndrome · Phase 2
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-il2
- cfz533
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04541589 | Phase 2 | Dec 18, 2020 | Novartis |
| NCT04129528 | Phase 2 | Oct 24, 2019 | Novartis |
| NCT03905525 | Phase 2 | Sep 16, 2019 | Novartis |
| NCT03781414 | Phase 2 | Jun 25, 2019 | Novartis |
| NCT03827798 | Phase 2 | Feb 27, 2019 | Novartis |
| NCT03663335 | Phase 2 | Jan 15, 2019 | Novartis |
| NCT03656562 | Phase 2 | Nov 2, 2018 | Novartis |
| NCT03610516 | Phase 2 | Sep 17, 2018 | Novartis |
| NCT02713256 | Phase 2 | Apr 19, 2016 | Novartis |
| NCT02565576 | Phase 2 | Sep 29, 2015 | Novartis |
| NCT02217410 | Phase 1/Phase 2 (Phase 2) | Feb 5, 2015 | Novartis |
| NCT02291029 | Phase 2 | Oct 22, 2014 | Novartis |
| NCT02089087 | Phase 1 | Jan 7, 2013 | Novartis |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 13 | 13 | 2 | 2013 |
1 organizations
Page 1 / 1